BioSpace News Archive

Wilk, a developer of authentic, cell-based human and animal milk and milk components, announced that it has joined Cellular Agriculture Europe, a coalition of companies committed to building a more resilient and sustainable future, as the first and currently only dairy company to join the association.

Vita Therapeutics announced the hiring of Amy Wesa, PhD, as Senior Vice President of Preclinical and Translational Research, Alexandra Capela, PhD, as Senior Vice President of Regulatory and IND Strategy, and Michael Kuo as Senior Vice President of Manufacturing.

Sen-Jam Pharmaceutical, an innovative life sciences company developing a portfolio of revolutionary anti-inflammatories by repurposing existing molecules for novel combination therapy, has entered a strategic partnership with KVK Tech.

Artelo Biosciences, Inc. announced it has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.

AppliedVR, a pioneer advancing the next generation of immersive therapeutics, today announced a new name for its flagship virtual reality (VR) therapeutic.

Vivalink, a leading provider of digital healthcare solutions, is providing its Biometric Data Platform to help detect neutropenic fever events.

Sysmex Corporation (Chairman and CEO: Hisashi Ietsugu; hereafter, “Sysmex”) and Eisai Co., Ltd. (CEO: Haruo Naito; hereafter, “Eisai”) are aiming to leverage their individual technologies and expertise in the creation of next-generation diagnostic agents that may aid in early diagnosis of dementia, treatment selection, and regular confirmation of treatment efficacy.

Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a Notice of Allowance has been received from the US Patent and Trademark Office (USPTO) for claims involving a novel method to treat cancer stem cells (CSC’s).

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William Stilley, Adial’s Chief Executive Officer will participate in a fireside chat at the 2022 Virtual Growth Conference.

Spotlight Therapeutics, Inc. today announced a $36.5M Series B financing to fuel a drive toward the clinic.